文章核心观点 - 公司Ardelyx Inc.被指在2023年10月31日至2024年7月1日期间发布了虚假和/或误导性的信息,人为推高了公司股票价格 [1][4] - 投资者在此期间购买了公司股票和期权,遭受了损失 [2][4] - 公司被指存在欺骗投资者公众的行为 [4] 根据相关目录分别进行总结 公司信息披露 - 公司被指在2023年10月31日至2024年7月1日期间发布了虚假和/或误导性的信息 [1][4] - 这些虚假和/或误导性信息人为推高了公司股票价格 [4] 投资者损失 - 投资者在此期间购买了公司股票和期权,遭受了损失 [2][4] 公司行为 - 公司被指存在欺骗投资者公众的行为 [4]

文章核心观点 - 根据投诉,在类别期内,被告未能披露Ardelyx尚未就是否将XPHOZAH(其用于降低透析患者血液中磷水平的药物,对于无法耐受或未能充分应对其他疗法的慢性肾病患者)纳入TDAPA做出最终决定,事实上,被告只有在首次审阅CMS提出的2025年ESRD PPS规则(于2024年6月27日发布)后,才能决定是否提交此类申请 [3] - 2024年7月2日,Ardelyx发布新闻稿宣布决定不将XPHOZAH纳入TDAPA,这一战略变化令市场震惊,消息公布后,Ardelyx股价下跌30.25%,每股收于5.28美元 [4] 根据相关目录分别进行总结 公司概况 - Ardelyx是一家专注于开发和商业化治疗慢性肾病患者的生物技术公司 [1] 公司业务 - Ardelyx开发了一种名为XPHOZAH的药物,用于降低透析患者血液中的磷水平 [3] - Ardelyx曾考虑是否将XPHOZAH纳入TDAPA(透析患者附加支付调整),但最终决定不提交此类申请 [3][4] 公司股价表现 - 2024年7月2日,Ardelyx股价下跌30.25%,每股收于5.28美元 [4] 诉讼信息 - 有投资者代表全体购买或以其他方式获得Ardelyx证券的人员和实体提起集体诉讼 [1] - 投资者如果希望担任集体诉讼的首席原告,必须在2024年10月15日前向法院提交相关文件 [5] - 该诉讼由Robbins LLP律师事务所负责,该所自2002年以来一直致力于维护股东权益 [6]

文章核心观点 - 该文章通知投资者,Ardelyx公司(NASDAQ: ARDX)面临集体诉讼,指控公司存在证券欺诈行为[1][2][4] - 该诉讼代表受到不利影响的Ardelyx投资者,时间范围为2023年10月31日至2024年7月1日[2] - 投资者可以在2024年10月15日之前申请成为该案件的首席原告,即使不担任首席原告也可以获得赔偿[5][6] 根据目录分类总结 诉讼相关 - 该诉讼由Levi & Korsinsky, LLP律所提起,该律所在证券诉讼领域有丰富经验,连续7年被评为美国前50大证券诉讼律所[7] - 投资者可以通过电子邮件或电话联系该律所获取更多信息[3][8] 诉讼指控 - 指控公司做出虚假陈述和隐瞒信息,人为推高并维持公司股票价格[4] - 这导致原告和其他集团成员以人为高的价格购买了公司股票和期权[4]

NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ardelyx investors who were adversely affected by alleged securities fraud between October 31, 2023 and July 1, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/ardelyx-lawsuit-submission-form? ...

NEW YORK, Aug. 22, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ardelyx, Inc. (NASDAQ: ARDX).Shareholders who purchased shares of ARDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/ardelyx-loss-submission-form/?id=97082&from=4CLASS PERIOD: October 31, 2023 to July 1, 2024 ...

NEW YORK, Aug. 21, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 15, 2024.So What: If you purchased Ardelyx securities during the Class Period ...

LOS ANGELES, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between October 31, 2023 and July 1, 2024, inclusive (the “Class Period”), ar ...

文章核心观点 - 公司Ardelyx在2023年10月31日、2024年5月2日和2024年2月22日的财报中表示将申请将XPHOZAH纳入TDAPA [1][2] - 但在2024年7月2日公司却突然披露决定不申请将XPHOZAH纳入TDAPA [2] - 这一消息导致公司股价下跌30.25%,收于每股5.28美元 [3] 根据相关目录分别进行总结 公司概况 - Ardelyx是一家上市公司,股票代码为NASDAQ: ARDX [1] - 本次诉讼涉及的时间区间为2023年10月31日至2024年7月1日 [1] 公司财报和公告 - 公司在2023年10月31日、2024年5月2日和2024年2月22日的财报中表示将申请将XPHOZAH纳入TDAPA [2] - 但在2024年7月2日公司却突然披露决定不申请将XPHOZAH纳入TDAPA [2] 股价变动 - 公司2024年7月2日的股价下跌30.25%,收于每股5.28美元 [3]

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 15, 2024. SO WHAT: If you purchased Ardelyx securities during the Class ...

ATLANTA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). The lawsuit alleges that Defendants indicated that Ardelyx would apply to include its product, XPHOZAH, in the Transitional Drug Add-on Payment Adjustment (“TDAPA”) when, in fact, Ardelyx had not yet reached a firm decision concerning whether or not to apply to include XPHOZAH in TDAPA, and could not, in fact, decide whether or not to submit such an applicat ...